Definium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Generalized Anxiety Disorder

Definium Therapeutics announced positive topline results from two Phase 3 trials, Voyage and Panorama, evaluating DT120 ODT for generalized anxiety disorder (GAD). Both studies met their primary and all key secondary endpoints, demonstrating statistically significant improvements on the Hamilton Anxiety Rating Scale compared to placebo. No drug-related serious adverse events or suicidality signals were observed. These findings, combined with a previous win in major depressive disorder, strengthen the case for a New Drug Application (NDA) filing in the first half of 2027.